Expert interprets FDA guidance on social media

01/9/2012 | Wall Street Journal, The

Drugmakers should be cautious when soliciting patient testimonials because discussions of off-label use could run afoul of recent FDA guidance, says Dale Cooke, vice president and group director of regulatory review at marketing shop Digitas Health. Drugmakers should also be careful with blogging about clinical trials tied to unapproved uses and ensure that conversations about off-label uses are not in a public forum, he said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT